Literature DB >> 9736759

Atypical antipsychotic drugs selectively increase neurotensin efflux in dopamine terminal regions.

J M Radke1, M J Owens, J C Ritchie, C B Nemeroff.   

Abstract

Typical antipsychotic drugs, such as haloperidol and chlorpromazine, increase synthesis of the neuropeptide neurotensin (NT) in both the striatum and the nucleus accumbens, whereas atypical antipsychotic drugs, such as clozapine and olanzapine, do so only in the nucleus accumbens. By using in vivo microdialysis, we now report that acute administration of haloperidol, clozapine, or olanzapine failed to alter the release of NT in either the striatum or nucleus accumbens. In contrast, chronic administration of haloperidol for 21 days increased NT release in both the striatum and nucleus accumbens, whereas treatment for 21 days with the atypical antipsychotic drugs, clozapine or olanzapine, increased NT release selectively in the nucleus accumbens. These findings suggest that (i) increased NT mRNA expression and NT tissue concentrations are associated with increases in the extracellular fluid concentrations of the peptide and (ii) atypical antipsychotic drugs may exert their therapeutic effects and produce fewer side effects by virtue of their selectivity in limbic compared with striatal, target neurons.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9736759      PMCID: PMC21665          DOI: 10.1073/pnas.95.19.11462

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  15 in total

1.  BMY 14802, a potential antipsychotic drug, increases expression of proneurotensin mRNA in the rat striatum.

Authors:  B Levant; K M Merchant; D M Dorsa; C B Nemeroff
Journal:  Brain Res Mol Brain Res       Date:  1992-02

Review 2.  Neurotensin, antipsychotic drugs, and schizophrenia. Basic and clinical studies.

Authors:  C B Nemeroff; B Levant; B Myers; G Bissette
Journal:  Ann N Y Acad Sci       Date:  1992       Impact factor: 5.691

3.  In vivo neurochemical and behavioural effects of intracerebrally administered neurotensin and D-Trp11-neurotensin on mesolimbic and nigrostriatal dopaminergic function in the rat.

Authors:  A P Ford; C A Marsden
Journal:  Brain Res       Date:  1990-11-26       Impact factor: 3.252

4.  Differential effects of antipsychotic drugs on the neurotensin concentration of discrete rat brain nuclei.

Authors:  C D Kilts; C M Anderson; G Bissette; T D Ely; C B Nemeroff
Journal:  Biochem Pharmacol       Date:  1988-04-15       Impact factor: 5.858

5.  Analysis of benzodiazepines and tricyclic antidepressants in serum using a common solid-phase clean-up and a common mobile phase.

Authors:  M Mazhar; S R Binder
Journal:  J Chromatogr       Date:  1989-12-29

6.  The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami.

Authors:  R Carraway; S E Leeman
Journal:  J Biol Chem       Date:  1973-10-10       Impact factor: 5.157

7.  CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder.

Authors:  R P Sharma; P G Janicak; G Bissette; C B Nemeroff
Journal:  Am J Psychiatry       Date:  1997-07       Impact factor: 18.112

8.  Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients.

Authors:  D L Garver; G Bissette; J K Yao; C B Nemeroff
Journal:  Am J Psychiatry       Date:  1991-04       Impact factor: 18.112

9.  Atypical neuroleptic-like behavioral effects of neurotensin.

Authors:  F B Jolicoeur; M A Gagné; R Rivest; A Drumheller; S St-Pierre
Journal:  Brain Res Bull       Date:  1993       Impact factor: 4.077

10.  CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates.

Authors:  N A Breslin; R L Suddath; G Bissette; C B Nemeroff; P Lowrimore; D R Weinberger
Journal:  Schizophr Res       Date:  1994-04       Impact factor: 4.939

View more
  7 in total

Review 1.  The role of neurotensin in central nervous system pathophysiology: what is the evidence?

Authors:  Fannie St-Gelais; Claudia Jomphe; Louis-Eric Trudeau
Journal:  J Psychiatry Neurosci       Date:  2006-07       Impact factor: 6.186

2.  Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating.

Authors:  E B Binder; B Kinkead; M J Owens; C D Kilts; C B Nemeroff
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

3.  Neurotensin triggers dopamine D2 receptor desensitization through a protein kinase C and beta-arrestin1-dependent mechanism.

Authors:  Dominic Thibault; Paul R Albert; Graciela Pineyro; Louis-Éric Trudeau
Journal:  J Biol Chem       Date:  2011-01-13       Impact factor: 5.157

4.  Sensorimotor gating in NTS1 and NTS2 null mice: effects of d-amphetamine, dizocilpine, clozapine and NT69L.

Authors:  Alfredo Oliveros; Michael G Heckman; Maria Del Pilar Corena-McLeod; Katrina Williams; Mona Boules; Elliott Richelson
Journal:  J Exp Biol       Date:  2010-12-15       Impact factor: 3.312

5.  Neurotensin-deficient mice show altered responses to antipsychotic drugs.

Authors:  P R Dobner; J Fadel; N Deitemeyer; R E Carraway; A Y Deutch
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-26       Impact factor: 11.205

Review 6.  Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration.

Authors:  P S Vosler; C S Brennan; J Chen
Journal:  Mol Neurobiol       Date:  2008-08-07       Impact factor: 5.590

7.  Severe recurrent hypothermia in an elderly patient with refractory mania associated with atypical antipsychotic, valproic acid and oxcarbazepine therapy.

Authors:  Oluwadamilare O Ajayi; Suzanne Holroyd
Journal:  BMJ Case Rep       Date:  2017-12-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.